Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

DIAmOND : An investigator-initiated, non-randomised, phase II study of combination CTLA-4 and PD-L1 blockade in advanced HER2-positive breast cancers who have progressed on prior trastuzumab-based therapy

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

TwoPhase Two

18+Age Over 18

Breast<br/>CancersCancer LocationBreast
Cancers

Systemic therapy | BreastBreast

Trial Overview Read MoreRead more

This phase II trial is trying to determine whether combining an anti-HER2 therapy (trastuzumab) with two immunotherapy drugs (durvalumab and tremelimumab) will improve clinical outcomes for patients that are diagnosed with advanced HER2+ breast cancer.
 

This trial is treating patients with HER2+ breast cancer.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.
  • You have previously been treated (or are currently being treated) on a clinical trial.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

An investigator-initiated, non-randomised, phase II study of combination CTLA-4 and PD-L1 blockade in advanced HER2-positive breast cancers who have progressed on prior trastuzumab-based therapy

Cooperative Group

Australian New Zealand Breast Cancer Trials Group (ANZBCTG)

Summary

This trial involves two phases of treatment; an induction phase (weeks 1-16) and a treatment phase (weeks 17-52). During the induction phase, patients will receive 4 doses of durvalumab (1 dose every 4 weeks); 4 doses of tremelimumab (1 dose every 4 weeks); and 16 doses of trastuzumab (1 dose every week), all administered intravenously. In this phase, Oestrogen-receptor-positive patients will also start or continue with endocrine therapy. In the treatment phase, patients will only receive durvalumab and trastuzumab every 3 weeks for 12 doses (total 36 weeks).

Recruiting Hospitals Read MoreRead more

Austin Health
Heidelberg
Ms Samantha Chakar
samantha.chakar@austin.org.au
03 9496 3088

Bendigo Hospital
Bendigo
Cancer Research
cancerresearch@bendigohealth.org.au
03 5454 8827

PCCTU (Parkville Cancer Clinical Trials Unit) *
Parkville
Heather Rootes
PCCTU.Breast@petermac.org

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next